SYDNEY: A novel mRNA Covid vaccination candidate has been developed by research institutes and a pharmaceutical business in Victoria, Australia, with clinical trials set to begin early next year. The vaccine candidate, which was created by Monash University researchers, IDT Australia, and the Peter Doherty Institute for Infection and Immunity, is predicted to protect against future Covid variations.

According to reports, Professor Colin Pouton of Monash University, who led the vaccine development team, said on Tuesday that the vaccine has the ability to swiftly modify its composition in response to evolving virus mutations, which is especially crucial as new strains emerge. Unlike existing vaccines, the new proposal focuses on a specific portion of the spike protein called the receptor-binding domain (RBD), which mediates the virus's ability to adhere to and enter cells.

This strategy, according to Pouton, results in a more targeted vaccine with the essential capacity to rapidly modify its composition in response to emerging mutations, such as the novel variation Omicron - if the virus mutates, a new vaccine may be tested in a matter of weeks. "The receptor-binding domain of the novel variation Omicron exhibits an unusual number of mutations. It's unclear how concerned we should be about this mutation, but our RBD mRNA vaccine programme is well-suited to developing a specialised vaccine to protect against it "he stated.

Global vaccination plan only way out to curb pandemic: Guterres

Omicron variant seen in previous test samples from November in Netherlands

Turkey is on high alert for the mutation Omicron Covid-19